secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001193125-22-238439
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics: FDA agrees single additional Phase 3 trial could support approval of tebipenem HBr for cUTI
--------------------------------------------------------------------------------

- FDA indicated positive results from one additional Phase 3 trial, plus confirmatory nonclinical evidence, could support approval.
- Spero plans to advance tebipenem HBr development and potential commercialization through external partnership.
- Type A meeting follows June 2022 CRL; FDA aligned on key components for pivotal trial design, with possible SPA.
- If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522238439/0001193125-22-238439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522238439/d331031d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-238439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer